You are here:

canagliflozin plus metformin (Vokanamet)

Advice

following an abbreviated submission

canagliflozin plus metformin (Vokanamet®) is accepted for restricted use within NHS Scotland.

Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

  • in patients not adequately controlled on their maximally tolerated doses of metformin alone;
  • n patients on their maximally tolerated doses of metformin along with other glucose-lowering medicinal products, including insulin, when these do not provide adequate glycaemic control;
  • in patients already being treated with the combination of canagliflozin and metformin as separate tablets.

SMC restriction: use in patients for whom a combination of canagliflozin and metformin is an appropriate choice of therapy

Canagliflozin in combination with metformin has been shown to be bioequivalent to canagliflozin and metformin administered separately and canagliflozin administered twice daily has been shown to provide similar exposure to the equivalent dose administered once daily.

Drug Details

Drug Name: canagliflozin plus metformin (Vokanamet)
SMC Drug ID: 1019/14
Manufacturer: Janssen-Cilag Ltd
Indication: In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 12 January 2015

Back